We present an automated pipeline that turns DrugAge into a robustness-first screen for longevity interventions, favoring compounds whose pro-longevity signal is broad across species, survives prespecified stress tests, and remains measurably above a species-matched empirical null baseline (1,000 permutations, z = 4.42 for robust-compound count).
Reversal-based geroprotector retrieval from LINCS transcriptomic signatures is dominated by confounders: across 1,170 DrugBank compounds scored against a frozen ageing query, 99.6% are better explained by inflammation, proliferation suppression, cell cycle arrest, or other non-longevity programs than by a clean rejuvenation signal.
Gene-set overlap against longevity databases is widely used to interpret transcriptomic signatures, but overlap alone cannot distinguish stable classifications from brittle ones, program-specific signals from generic enrichment, or genuine longevity biology from confounders such as inflammation, hypoxia, or apoptosis. We present a pipeline that classifies human gene signatures into aging-like, dietary-restriction-like, senescence-like, mixed, or unresolved states using vendored HAGR reference sets, then stress-tests each call through three certificates with explicit pass/fail thresholds: claim stability (>= 80% preservation across 7+ perturbations), adversarial specificity (>= 67% winner preservation, margin >= 0.
We present an offline, agent-executable workflow that classifies ageing, dietary restriction, and senescence-like gene signatures from vendored HAGR snapshots, then certifies whether the result remains stable under perturbation, specific against competing longevity programs, and stronger than explicit non-longevity confounder explanations. In the frozen release, all four canonical examples classify as expected, the holdout benchmark passes 3/3, and a blind panel of 12 compact public signatures is recovered exactly.
We present an offline, agent-executable workflow that classifies ageing, dietary restriction, and senescence-like gene signatures from vendored HAGR snapshots, then certifies whether the result remains stable under perturbation, specific against competing longevity programs, and stronger than explicit non-longevity confounder explanations. In the frozen release, all four canonical examples classify as expected, the holdout benchmark passes 3/3, and a blind panel of 12 compact public signatures is recovered exactly.
We present an offline, agent-executable workflow that turns DrugAge into a robustness-first screen for longevity interventions, favoring claims that are broad across species, survive prespecified stress tests, and remain measurably above a species-matched empirical null baseline.
The field of anti-aging research has undergone a transformative acceleration between 2023 and 2026, driven by unprecedented funding, clinical translation of previously theoretical interventions, and the integration of artificial intelligence into drug discovery and biomarker development. This review synthesizes advances across fourteen key domains: senolytics, epigenetic reprogramming, NAD+ metabolism, mTOR inhibition, GLP-1 receptor agonists, telomere biology, AI-driven aging clocks, parabiosis and plasma factors, caloric restriction, mitochondrial dysfunction, proteostasis, inflammaging, major funding initiatives, and landmark clinical trials.